CRM · Salesforce, Inc. · Stock research

Current Thesis

The leg on offer is a de-rating reversal, not a growth story. Salesforce closed at $192.74 on 2026-08-07, 27.2% below its 52-week high of $264.88, against FY27 non-GAAP diluted EPS guidance of $14.06–$14.12 issued with the Q1 FY27 release on 2026-05-27 — roughly 13.8x forward earnings per stockanalysis.com's 2026-08-07 screen. What changed in July is that the agentic product line produced a single verifiable dollar figure: a $1.6B, three-year agentic enterprise license agreement from the U.S. Department of Veterans Affairs, announced 2026-07-24, which moved the stock 7% on 2026-07-27. The 2026-08-26 Q2 FY27 print, after the close, decides whether that is the start of a re-rating or a one-contract headline inside a decelerating seat-based franchise.

Life-cycle: MATURING. The Agentforce narrative is fully distributed — it is why the stock carried a premium into 2025 and why Benzinga could run the headline "Why is Salesforce the Worst-Performing Dow Jones Stock?" on 2026-07-25. Morgan Stanley's 2026-07-21 downgrade to Equal-Weight with the target cut from $287 to $185 is sell-side moving to neutral on a name it already owned the thesis on. Working operationally (cRPO +14% Y/Y in Q1 FY27), moderating in flow, with one fresh dated catalyst — the federal ELA — that has not yet been repeated.

Bullish and bearish views on Salesforce, Inc.

The model's bull view on Salesforce, Inc. (CRM), in brief: Q1 FY27 (reported 2026-05-27): revenue $11.13B, +13% Y/Y; cRPO $33.6B, +14% Y/Y; total RPO $67.9B, +11% Y/Y. Bookings growth running ahead of reported revenue growth is the specific number the bear case has to break. The bear view: Morgan Stanley's Adam Wood cut CRM to Equal-Weight on 2026-07-21 and took the target from $287 to $185 — a 35% reduction that lands below the 2026-08-07 close. Both cases follow in full.

Bull Case

• Q1 FY27 (reported 2026-05-27): revenue $11.13B, +13% Y/Y; cRPO $33.6B, +14% Y/Y; total RPO $67.9B, +11% Y/Y. Bookings growth running ahead of reported revenue growth is the specific number the bear case has to break.
• FY27 revenue guidance raised to $45.9–$46.2B (+11% Y/Y) at the Q1 print, with full-year non-GAAP operating margin guided to 34.3% and GAAP to 20.6%. A guide going up while the multiple goes down is the entire arithmetic of the setup.
• Agentforce and Data 360 combined ARR of $3.4B, with Agentforce ARR up more than 200% Y/Y as disclosed at the Q1 FY27 release. The base is small against $42.83B trailing revenue (stockanalysis.com, 2026-08-07), but it is a disclosed line rather than a slide.
• The VA award, announced 2026-07-24, is $1.6B over three years covering services to more than 17 million veterans — a federal agentic deployment at contract scale, in the same week Oracle's $7B defense deal was reported. Government agentic buying is showing up as awarded dollars.
• Valuation gap is wide and dispersed: consensus target $241.72 across 53 analysts, low $160, high $475 (stockanalysis.com, 2026-08-07). Trailing P/E 22.37 versus forward 13.84 on EPS of $8.61.

Bear Case

• Morgan Stanley's Adam Wood cut CRM to Equal-Weight on 2026-07-21 and took the target from $287 to $185 — a 35% reduction that lands below the 2026-08-07 close. The most recent full re-underwrite by a major desk sits under the market price.
• The disruption trade is live and priced elsewhere in the group. UiPath fell 13% on 2026-07-22 on OpenAI's "Presence" enterprise platform launch. Seat-based application software is the direct target of that product category, and CRM is the largest seat-based franchise in the index.
• Slack, acquired for roughly $28B, now faces a purpose-built competitor from Jack Dorsey (reported 2026-07-22). No revenue impact is measurable yet; the risk is to the multiple, not the quarter.
• FY27 growth is partly inorganic. Salesforce attributed Q1 FY27 growth to Agentforce, Data 360, Slack and the Informatica acquisition. Organic growth is the number to isolate on 2026-08-26.
• FY2026 revenue was $41.53B, +9.58% over FY2025's $37.90B — the compounding rate is single-digit before acquisitions, which is why the de-rating happened in the first place.
• Steve Eisman's 2026-07-15 remark that AI firms have "no moats" is a sentiment marker, not evidence, but it dates the macro overhang the group is trading under.

Setup & Price Structure

Close $192.74 (2026-08-07), RSI(14) 61.8, three-month return +6.3%, 27.2% below the 52-week high of $264.88. Price sits between two named levels: Morgan Stanley's $185 target underneath and the $211 resistance Benzinga flagged on 2026-07-28 after the stock "jumped past short-term moving averages" on the VA news. Neither has been resolved.

Positioning observables, stated without a verdict on them:

• The 2026-07-27 advance was 7% in one session on a contract announcement — a gap driven by news, which leaves an unfilled zone beneath price.
• Retail-attention coverage clustered hard in a two-week window: three "Why is Salesforce stock surging/falling" explainers (2026-07-21, 07-27, 07-28) plus two twenty-year-return retrospectives (2026-07-22, 2026-08-04) and a "Salesforce Stock Is Gaining Monday: What's Going On?" on 2026-08-03. The 20-year-hypothetical-return format is an attention genre, and it appeared twice in thirteen days.
• CRM appeared in Benzinga's IT whale-activity options scans on 2026-07-24 and 2026-08-06.
• Market capitalization was quoted at $138.82B by Benzinga on 2026-07-22 and $157.85B by stockanalysis.com on 2026-08-07 (different sources, different dates — the direction is the point).
• Earnings land 2026-08-26, eighteen calendar days from the price basis. No insider transactions appear in the filing record reviewed for this note.
• The name is a Dow Jones Industrial Average component and was the index's worst performer as of 2026-07-25, meaning index-level rebalancing flow is a persistent presence in the tape.

The structure is a stock that has rallied into a print off a downgrade low, is not extended against its own 52-week range, and carries a positive but not stretched momentum reading.

Catalyst Calendar (next 30 days)

• 2026-08-26 (confirmed, after market close): Q2 FY27 earnings release and 2:00pm PT / 5:00pm ET call. Guidance issued 2026-05-27 was $11.27–$11.35B for the quarter, +10–11% Y/Y.
• 2026-08-26: FY27 full-year guide reset in the same release — whether $45.9–$46.2B and non-GAAP EPS $14.06–$14.12 hold, rise, or come down.
• 2026-08-26: cRPO print. Q1 FY27 was $33.6B, +14% Y/Y. This is the single line the LLM-disruption thesis has to show cracking.
• ~2026-08-27 to 2026-09-04 (est.): post-print analyst target revisions. Morgan Stanley's $185 (2026-07-21) is the marker to watch for restoration or confirmation.
• No other company-controlled dated event falls inside the window. Dreamforce is an autumn event and its 2026 date is outside the next 30 days.

What Would Change Our Mind

The structure that has to hold is the July contract advance. A daily close below $180 gives back the entire move that followed the 2026-07-24 VA announcement and returns the stock beneath the $185 target Morgan Stanley set on 2026-07-21 — at which point the market has voted that a $1.6B three-year federal ELA did not change the earnings path, and the de-rating case is the operative one.

The fundamental break is separable and lands on one date. If the 2026-08-26 release shows cRPO growth decelerating materially from the +14% Y/Y posted in Q1 FY27, or the FY27 revenue guide of $45.9–$46.2B is trimmed rather than held or raised, the "cheap and compounding" frame stops describing the company. Equally: a beat-and-raise on 2026-08-26 that is followed by a lower close inside the following week would say the multiple is the constraint and no operating result fixes it in this tape.

On the upside, a weekly close above $211 clears the resistance shelf Benzinga identified on 2026-07-28 and would mark the first structural break in the twelve-month downtrend.

A second federal or large-enterprise agentic ELA disclosed at similar scale to the VA award would move the read from MATURING toward a re-accelerating one; a full quarter passing with no repeat would confirm the single-contract interpretation.

Correlation Notes

• Seat-based application software as a factor. The UiPath -13% session on 2026-07-22, triggered by OpenAI's "Presence" enterprise launch, is the cleanest proxy for what a fresh LLM-native product announcement does to this complex. CRM has the largest seat exposure in it.
• Federal AI contracting. Oracle's $7B defense award and the CRM $1.6B VA award landed in the same reporting week (week of 2026-07-20). Government agentic budgets are a shared driver, and shared exposure to appropriations risk.
• Dow versus Nasdaq divergence. The Nasdaq 100 entered correction on 2026-07-28 during a chip rout while CRM was rallying on its own contract news. The July move was idiosyncratic, which cuts both ways — it does not have index beta supporting it.
• Data/integration adjacency. Informatica now sits inside the reported numbers, linking CRM's growth line to enterprise data-management demand rather than pure CRM seats.
• Collaboration software. Slack's competitive position is now a named narrative (Dorsey, 2026-07-22) that will trade on product headlines rather than on Salesforce's own disclosure cadence.